REG-The Biotech Growth Trust PLC: BioMarin Pharmaceuticals to acquire BIOG portfolio company, Amicus Therapeutics

Biotech Growth TrustAnnouncement

Mon 13:00

For immediate release

22 December 2025

THE BIOTECH GROWTH TRUST PLC

("BIOG" or the "Company")

BioMarin Pharmaceuticals to acquire BIOG portfolio company, Amicus
Therapeutics.

The Company notes the announcement on Friday, 19 December 2025 that BioMarin
Pharmaceuticals Inc. ("BioMarin") has entered into an agreement to acquire
BIOG portfolio company, Amicus Therapeutics ("Amicus") for approximately $4.8
billion, or $14.50 per share, in cash, representing a 33% premium to Amicus'
closing price on Thursday, 18 December 2025.

Amicus is a global, patient-dedicated biotechnology company focused on
discovering, developing and delivering novel high-quality medicines for people
living with rare diseases. The acquisition will strengthen BioMarin's
commercial portfolio, adding two new treatments to the company's existing
portfolio of medicines that target lysosomal storage disorders. Amicus also
has U.S. rights to DMX-200, a potential first-in-class investigational small
molecule for the treatment of focal segmental glomerulosclerosis (FSGS), a
rare and fatal kidney disease in Phase 3 development. 

The Company's holding in Amicus represented 2.7% of the Company's net asset
value at the time of the announcement.   The transaction is reflected in the
Company's NAV as at close of business on 19 December 2025, which was announced
earlier today.

To sign up for BIOG updates by email, please click                            
                               here                             
(https://www.biotechgt.com/media/email-alerts)                             .

Enquiries:

SEC Newgate                                                           (George
Esmond)

Public Relations

020 3757 6894

Frostrow Capital LLP

Company Secretary

020 3709 8734



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved